Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological advances, other innovative biologics, such as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2021-01-01
Colecção:mAbs
Assuntos:
Biobetter
biologic
biosimilar
CT-P13
infliximab
innovative biologics
Acesso em linha:https://www.tandfonline.com/doi/10.1080/19420862.2020.1868078
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados